Figure 2.
Comparison of TDP-43 (A); Aβ-42 (B); τP-181 (C) and τT (D) levels and τP-181/τT ratio (E) in C9orf72 hexanucleotide repeat expansion carriers (C9orf72+) and non-carriers (C9orf72−). Analyses were performed separately for FTD patients and ALS (with or without FTD) patients. In patients with ALS (with or without concurrent FTD), levels of τP-181 were lower in C9orf72 carriers compared to non-carriers (C). All other comparisons yielded non-significant results.